After a $3B exit, a biopharma veteran unveils a new company and a global focus

June 30, 2021 Auto Bot BioPharma, cancer, China, deals, investing, Pennsylvania, Pharma, Startups 0

Led by former Viela Bio CEO Bing Yao, ArriVent Biopharma secures rights to drugs from emerging biotech hubs, then develops them for Western markets. The biotech’s first asset is a cancer drug licensed from Shanghai-based Allist Pharmaceuticals.